141 related articles for article (PubMed ID: 19070518)
1. Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.
Saigal CS; Deibert CM; Lai J; Schonlau M
Urol Oncol; 2010; 28(3):308-13. PubMed ID: 19070518
[TBL] [Abstract][Full Text] [Related]
2. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
[TBL] [Abstract][Full Text] [Related]
3. Race and sex differences in the receipt of timely and appropriate lung cancer treatment.
Shugarman LR; Mack K; Sorbero ME; Tian H; Jain AK; Ashwood JS; Asch SM
Med Care; 2009 Jul; 47(7):774-81. PubMed ID: 19536007
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
5. Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: a comorbidity-controlled competing-risks model.
Patel HD; Kates M; Pierorazio PM; Allaf ME
Urol Oncol; 2014 Jul; 32(5):576-83. PubMed ID: 24629500
[TBL] [Abstract][Full Text] [Related]
6. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
[TBL] [Abstract][Full Text] [Related]
7. The effect of race and gender on the surgical management of the small renal mass.
Kates M; Whalen MJ; Badalato GM; McKiernan JM
Urol Oncol; 2013 Nov; 31(8):1794-9. PubMed ID: 22687567
[TBL] [Abstract][Full Text] [Related]
8. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
9. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?
Keating NL; Kouri E; He Y; Weeks JC; Winer EP
Med Care; 2009 Jul; 47(7):765-73. PubMed ID: 19536008
[TBL] [Abstract][Full Text] [Related]
10. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
11. Racial disparities in treatment of high-grade endometrial cancer in the Medicare population.
Rauh-Hain JA; Buskwofie A; Clemmer J; Boruta DM; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Apr; 125(4):843-851. PubMed ID: 25751197
[TBL] [Abstract][Full Text] [Related]
12. Racial disparities in treatment use for multiple myeloma.
Fiala MA; Wildes TM
Cancer; 2017 May; 123(9):1590-1596. PubMed ID: 28085188
[TBL] [Abstract][Full Text] [Related]
13. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
[TBL] [Abstract][Full Text] [Related]
14. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
Reeder-Hayes K; Peacock Hinton S; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2016 Jun; 34(17):2003-9. PubMed ID: 27069085
[TBL] [Abstract][Full Text] [Related]
15. Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults.
Guadamuz JS; Ozenberger K; Qato DM; Ko NY; Saffore CD; Adimadhyam S; Cha AS; Moran KM; Sweiss K; Patel PR; Chiu BC; Calip GS
Medicine (Baltimore); 2019 Nov; 98(46):e17960. PubMed ID: 31725657
[TBL] [Abstract][Full Text] [Related]
16. Residual treatment disparities after oncology referral for rectal cancer.
Morris AM; Billingsley KG; Hayanga AJ; Matthews B; Baldwin LM; Birkmeyer JD
J Natl Cancer Inst; 2008 May; 100(10):738-44. PubMed ID: 18477800
[TBL] [Abstract][Full Text] [Related]
17. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study.
Lai Y; Wang C; Civan JM; Palazzo JP; Ye Z; Hyslop T; Lin J; Myers RE; Li B; Jiang B; Sama A; Xing J; Yang H
Gastroenterology; 2016 May; 150(5):1135-1146. PubMed ID: 26836586
[TBL] [Abstract][Full Text] [Related]
18. Racial disparities in the treatment of advanced epithelial ovarian cancer.
Howell EA; Egorova N; Hayes MP; Wisnivesky J; Franco R; Bickell N
Obstet Gynecol; 2013 Nov; 122(5):1025-1032. PubMed ID: 24104782
[TBL] [Abstract][Full Text] [Related]
19. Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.
Penn DC; Chang Y; Meyer AM; DeFilippo Mack C; Sanoff HK; Stitzenberg KB; Carpenter WR
Cancer; 2015 Jan; 121(1):93-101. PubMed ID: 25209056
[TBL] [Abstract][Full Text] [Related]
20. Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer.
Sail K; Franzini L; Lairson D; Du X
Ethn Health; 2012; 17(3):309-23. PubMed ID: 22066691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
